Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the pharmacodynamic effect of ticagrelor dosing (180mg
LD/ 90mg BID) at 2, 4 hours and 14 days in stable Coronary artery disease (CAD) patients who
exhibit high-on prasugrel platelet reactivity defined as Vasodilator Stimulated
Phosphoprotein-Phosphorylation (VASP-P) >50%.